Oncolytics Biotech Stock Performance
| ONCY Stock | USD 0.93 0.02 2.11% |
Oncolytics Biotech has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of -0.64, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Oncolytics Biotech are expected to decrease at a much lower rate. During the bear market, Oncolytics Biotech is likely to outperform the market. Oncolytics Biotech right now holds a risk of 5.6%. Please check Oncolytics Biotech total risk alpha, as well as the relationship between the downside variance and daily balance of power , to decide if Oncolytics Biotech will be following its historical price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent fundamental indicators, Oncolytics Biotech may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Last Split Factor 10:95 | Dividend Date 2018-05-25 | Last Split Date 2018-05-25 |
1 | Oncolytics Biotech to Participate in Fireside Chats at Two Investment Conferences in September | 09/06/2024 |
2 | Oncolytics Biotechs Buy Rating Reaffirmed at HC Wainwright | 09/23/2024 |
3 | Oncolytics Biotech Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path | 10/04/2024 |
4 | Oncolytic Virus Therapy Market Set to Witness Significant Growth by 2024-2031Oncolytics Biotech Inc, Circio Holding ASA | 10/14/2024 |
5 | Oncolytics Biotech Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 11/13/2024 |
6 | Oncolytics Biotech Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
| Begin Period Cash Flow | 11.7 M |
Oncolytics |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 95.00 in Oncolytics Biotech on August 31, 2024 and sell it today you would lose (2.00) from holding Oncolytics Biotech or give up 2.11% of portfolio value over 90 days. Oncolytics Biotech is currently generating 0.1093% in daily expected returns and assumes 5.5979% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Oncolytics, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncolytics Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncolytics Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncolytics Biotech, and traders can use it to determine the average amount a Oncolytics Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0195
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ONCY | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.6 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Oncolytics Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncolytics Biotech by adding it to a well-diversified portfolio.
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -1.38 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | 58.1 M | ||||
| Shares Outstanding | 77.07 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 11.12 X | ||||
| EBITDA | (33.71 M) | ||||
| Net Income | (27.75 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 423 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (28.45 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 75.82 M | ||||
| Total Asset | 38.82 M | ||||
| Retained Earnings | (446 M) | ||||
| Working Capital | 33.94 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
About Oncolytics Biotech Performance
Evaluating Oncolytics Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncolytics Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncolytics Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.98) | (1.03) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (1.01) | (0.96) |
Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech had very high historical volatility over the last 90 days | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (27.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (28.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from insidermonkey.com: Oncolytics Biotech Inc. Q3 2024 Earnings Call Transcript |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.